The UK reports 25 fresh cases of thrombosis associated with the AstraZeneca vaccine

The United Kingdom has received 30 reports of rare blood coagulation events in recent weeks related to the Oxford / AstraZeneca Covid-19 vaccine, imposing preventative restrictions on its use in many European countries.

Thursday night, Medicines and Healthcare Products Regulatory Agency Public information In addition to the 5 cases reported earlier this month, about 25 new cases of severe and very rare blood coagulation events.

MHRA also revealed that individuals vaccinated with the BioNTech / Pfizer vaccine did not have the same response.

Concerns are rising Links between AstraZeneca Jab A very special and rare type of blood coagulation event. The news that their numbers have been confirmed to be increasing in the UK could question the view that this is a phenomenon purely found in mainland Europe.

According to reports of similar incidents, France, Sweden, Finland, Canada, Recently Germany It is recommended to avoid shots for young people who are much more likely to be affected by the condition. Vaccines are still discontinued in Norway and Denmark.

The main condition that causes an alarm is called cerebral sinus thrombosis (CVST), when blood forms a blood clot in a vein flowing from the brain, which can be a fatal complication.

When concerned, this is combined with a problem called thrombocytopenia, where patients show abnormally low levels of platelets and cause heavy bleeding.

In Norway, health officials have reported at least 6 of Jab’s 120,000 recipients of such cases, four of whom died. In Germany, 31 cases have been reported after 2.7 million vaccinations, 29 of which are women aged 20-63 and two men aged 36-57. Nine of them have died.

By March 24, MHRA had received 22 reports of CVST and 8 reports of other thrombotic events with low platelets out of a total of 18.1 million doses of AstraZeneca vaccine. This corresponds to approximately one case for every 600,000 recipients.

In the UK, there were 17 CVST reports this week compared to the previous week.

British officials say there is insufficient evidence at this time to make changes to vaccination policy. Also, even if a causal relationship is established, the occurrence of blood clots seems to be very rare, so it makes sense for some UK-based experts to continue vaccination. Some have mentioned it.

Johannes Oldenberg, a professor of transfusion medicine at the University of Bonn, said he agreed with the British decision, even though he believed that AstraZeneca’s firing was causing the symptoms.

“If you had the option of immediate vaccination with AstraZeneca or waiting for Moderna for 4 weeks, you would choose AstraZeneca vaccine because 4-week prophylaxis far outweighs this risk,” he said.

Oxford University and AstraZeneca say their trials show that the vaccine is safe and effective and continues to monitor side effects as shots are deployed.

Dr. June Raine, Chief of MHRA, said, “The benefits of the Covid-19 vaccine AstraZeneca in the prevention of Covid-19 infection and its complications continue to outweigh the risks, and the general public is invited when invited. You should continue to get the vaccine, “he said repeatedly. ..

The UK reports 25 fresh cases of thrombosis associated with the AstraZeneca vaccine

Source link The UK reports 25 fresh cases of thrombosis associated with the AstraZeneca vaccine

Back to top button